This company has been marked as potentially delisted and may not be actively trading. Digirad (DRAD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock DRAD vs. NRXS, QTI, VRAYQ, VIVE, ELMD, BMGL, CLGN, RADX, POCI, and NMTCShould you be buying Digirad stock or one of its competitors? The main competitors of Digirad include NeurAxis (NRXS), QT Imaging (QTI), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), Basel Medical Group (BMGL), CollPlant Biotechnologies (CLGN), Radiopharm Theranostics (RADX), Precision Optics (POCI), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical" sector. Digirad vs. Its Competitors NeurAxis QT Imaging ViewRay Viveve Medical Electromed Basel Medical Group CollPlant Biotechnologies Radiopharm Theranostics Precision Optics NeuroOne Medical Technologies Digirad (NASDAQ:DRAD) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk. Which has more risk & volatility, DRAD or NRXS? Digirad has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.1, suggesting that its share price is 210% more volatile than the S&P 500. Do institutionals and insiders have more ownership in DRAD or NRXS? 11.4% of Digirad shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 12.5% of Digirad shares are owned by company insiders. Comparatively, 15.2% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is DRAD or NRXS more profitable? Digirad has a net margin of -5.32% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Digirad's return on equity.Company Net Margins Return on Equity Return on Assets Digirad-5.32% -3.75% -0.85% NeurAxis -492.76%N/A -641.25% Do analysts prefer DRAD or NRXS? NeurAxis has a consensus target price of $7.00, suggesting a potential upside of 183.40%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than Digirad.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Digirad 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, DRAD or NRXS? Digirad has higher revenue and earnings than NeurAxis. Digirad is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDigirad$114.18M0.09-$4.63M-$0.35-6.09NeurAxis$3.22M5.54-$14.63M-$0.99-2.49 Does the media refer more to DRAD or NRXS? In the previous week, NeurAxis had 1 more articles in the media than Digirad. MarketBeat recorded 1 mentions for NeurAxis and 0 mentions for Digirad. Digirad's average media sentiment score of 0.00 beat NeurAxis' score of -0.34 indicating that Digirad is being referred to more favorably in the media. Company Overall Sentiment Digirad Neutral NeurAxis Neutral SummaryNeurAxis beats Digirad on 9 of the 16 factors compared between the two stocks. Get Digirad News Delivered to You Automatically Sign up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRAD vs. The Competition Export to ExcelMetricDigiradElectromedical Equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.14M$39.68M$5.82B$9.73BDividend Yield83.65%N/A3.84%4.09%P/E Ratio-0.683.4131.1525.96Price / Sales0.09250.60474.77122.97Price / Cash0.6941.3637.1558.38Price / Book0.212.259.116.39Net Income-$4.63M-$2.66M$3.26B$265.56M Digirad Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRADDigiradN/A$2.13flatN/A-52.8%$10.14M$114.18M-0.68618NRXSNeurAxis2.4442 of 5 stars$2.49+2.5%$7.00+181.1%-26.9%$17.97M$2.93M-1.3519QTIQT ImagingN/A$1.90+2.7%N/A+361.2%$10.72M$4.00M0.00N/AVRAYQViewRayN/AN/AN/AN/A$18K$102.21M0.00300High Trading VolumeVIVEViveve MedicalN/A$0.00flatN/AN/A$1K$6.83M0.0070ELMDElectromed1.8517 of 5 stars$19.34+1.0%$33.50+73.2%+28.9%$162.19M$61.44M25.79160Positive NewsBMGLBasel Medical GroupN/A$2.18+5.3%N/AN/A$38.20MN/A0.0036Positive NewsLockup ExpirationGap DownCLGNCollPlant Biotechnologies2.6645 of 5 stars$3.15+5.7%$11.50+265.1%-50.6%$37.89M$510K-2.5870News CoverageEarnings ReportAnalyst ForecastGap DownRADXRadiopharm TheranosticsN/A$5.22+10.8%$15.00+187.4%N/A$37.13MN/A0.00N/AGap DownHigh Trading VolumePOCIPrecision Optics0.108 of 5 stars$4.70-2.7%N/A-11.5%$37.03M$19.10M-5.2880Gap UpNMTCNeuroOne Medical Technologies2.9509 of 5 stars$0.80+7.8%$1.45+82.2%-0.1%$36.78M$3.45M-3.6220 Related Companies and Tools Related Companies NeurAxis Competitors QT Imaging Competitors ViewRay Competitors Viveve Medical Competitors Electromed Competitors Basel Medical Group Competitors CollPlant Biotechnologies Competitors Radiopharm Theranostics Competitors Precision Optics Competitors NeuroOne Medical Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRAD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Digirad Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Digirad With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access